News | Antiplatelet and Anticoagulation Therapies | December 17, 2018

Daily Aspirin Use May Do More Harm Than Good for Healthy People

Meta-analysis of 11 aspirin therapy clinical trials finds no reduction in cardiovascular events, increased risk of major bleeding

Daily Aspirin Use May Do More Harm Than Good for Healthy People

December 17, 2018 — Among otherwise healthy people, a daily dose of aspirin does not save lives and causes additional bleeding, a new analysis has found. The meta-analysis of 11 aspirin therapy clinical trials involving more than 157,000 healthy individuals since the 1980s found the drug does not reduce deaths, heart attacks and strokes. Low-dose aspirin users were also about 50 percent more likely to have major bleeding compared with those who did not use aspirin, the researchers concluded. The findings were published Dec. 17 in the European Heart Journal.1

Aspirin prevents blood clots from forming, which can reduce the risk of a stroke or heart attack. But it can also be a hazard: Blood that does not clot easily can raise the risk of a hemorrhagic stroke or internal bleeding. Some 40 percent of U.S. adults over age 50 use aspirin for the primary or secondary prevention of cardiovascular disease, according to a 2016 study.

The analysis affirms more broadly the findings of three large-scale, randomized clinical trials done elsewhere and published earlier this year. Like the current meta-analysis, those studies concluded that aspirin had no effect on death rates but caused more bleeding among otherwise heart-healthy patients. Some studies of aspirin’s potential cardiovascular benefits emerged in the 1980s but subsequent research revealed its limitations and potential hazards.

Because much of the aspirin therapy data come from very old studies that may have less relevance to current practice, a new, in-depth analysis was needed, said Anthony A. Bavry, M.D., an associate professor in the UF College of Medicine’s Department of Medicine and a cardiologist at the Malcom Randall Veterans Affairs Medical Center in Gainesville, Fla.   

To establish their findings, Bavry and his collaborators parsed mortality and other data on strokes, heart attacks and bleeding from the earlier studies. All-cause mortality was similar between aspirin and non-aspirin users who had no prior cardiovascular events (i.e., otherwise healthy individuals), which researchers said shows that the drug has no effect on death rates. Aspirin use also increased the incidence of major bleeding compared with non-users, the researchers found. Major bleeding was defined as blood loss that required hospitalization, surgery or transfusion, as well as all brain-related bleeding.

The research team closely scrutinized data from the 11 trials, looking for even small reductions in death and other risks associated with aspirin use.

“With the addition of each trial to our study, there wasn’t any evidence of added benefits regarding mortality. We actually found it might be futile to do any more trials to assess this outcome,” said Ahmed N. Mahmoud, M.D., a cardiology fellow in the UF College of Medicine’s department of medicine and a co-author of the study.

The findings largely reflect existing European guidelines for aspirin therapy, which recommend patients who are cardiovascular disease-free not use the drug due to the increased risk of major bleeding. Domestically, the current recommendations are more lenient: Mahmoud said U.S. guidelines still lean toward using aspirin therapy in certain patients with high risk of cardiovascular disease.

Despite aspirin’s entrenched status as a cornerstone medication, the most recent clinical studies and the UF Health-led meta-analysis make a strong case about the drug’s risks and lack of benefits among certain patients, Bavry said.

“Many professionals have a hard time believing that aspirin may not be so beneficial because there has been such a widespread and favorable view of this medication. This certainly does not settle the debate but it does call for a reappraisal of society’s overwhelmingly positive view of aspirin therapy,” he said.

Patients who are on a daily aspirin regimen or considering it for cardiovascular issues should talk to their healthcare provider to help them balance potential risks and benefits, Bavry said.

For more information:



1. Mahmoud A.N., Gad M.M., Elgendy A.Y., et al. Efficacy and safety of aspirin for primary prevention of cardiovascular events, a meta-analysis and trial sequential analysis of randomized controlled trials. European Heart Journal, published online Dec. 17, 2018.  doi:10.1093/eurheartj/ehy813.

Related Content

People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people sto
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer...
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for...
Experimental Vaccine May Reduce Post-Stroke Blood Clot Risk
News | Antiplatelet and Anticoagulation Therapies | November 01, 2018
A vaccine may one day be able to replace oral blood thinners to reduce the risk of secondary strokes caused by blood...
Overlay Init